232 related articles for article (PubMed ID: 37028502)
1. COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease.
Kronenberger T; Laufer SA; Pillaiyar T
Drug Discov Today; 2023 Jun; 28(6):103579. PubMed ID: 37028502
[TBL] [Abstract][Full Text] [Related]
2. Conventional Understanding of SARS-CoV-2 M
Zhou K; Chen D
Chembiochem; 2023 Nov; 24(22):e202300301. PubMed ID: 37577869
[TBL] [Abstract][Full Text] [Related]
3. Analyzing 3D structures of the SARS-CoV-2 main protease reveals structural features of ligand binding for COVID-19 drug discovery.
Xu L; Chen R; Liu J; Patterson TA; Hong H
Drug Discov Today; 2023 Oct; 28(10):103727. PubMed ID: 37516343
[TBL] [Abstract][Full Text] [Related]
4. Anti-HIV and anti-HCV small molecule protease inhibitors in-silico repurposing against SARS-CoV-2 M
Sultan A; Ali R; Ishrat R; Ali S
J Biomol Struct Dyn; 2022; 40(23):12848-12862. PubMed ID: 34569411
[TBL] [Abstract][Full Text] [Related]
5. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
Akaji K; Konno H
Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
[TBL] [Abstract][Full Text] [Related]
6. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.
Martorana A; Gentile C; Lauria A
Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574
[TBL] [Abstract][Full Text] [Related]
7. The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022.
Pang X; Xu W; Liu Y; Li H; Chen L
Eur J Med Chem; 2023 Sep; 257():115491. PubMed ID: 37244162
[TBL] [Abstract][Full Text] [Related]
8. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
9. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
10. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
[TBL] [Abstract][Full Text] [Related]
11. Circadian clock modulating small molecules repurposing as inhibitors of SARS-CoV-2 M
Sultan A; Ali R; Sultan T; Ali S; Khan NJ; Parganiha A
Chronobiol Int; 2021 Jul; 38(7):971-985. PubMed ID: 33820462
[TBL] [Abstract][Full Text] [Related]
12. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M
Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166
[TBL] [Abstract][Full Text] [Related]
13. Large library docking for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors.
Fink EA; Bardine C; Gahbauer S; Singh I; Detomasi TC; White K; Gu S; Wan X; Chen J; Ary B; Glenn I; O'Connell J; O'Donnell H; Fajtová P; Lyu J; Vigneron S; Young NJ; Kondratov IS; Alisoltani A; Simons LM; Lorenzo-Redondo R; Ozer EA; Hultquist JF; O'Donoghue AJ; Moroz YS; Taunton J; Renslo AR; Irwin JJ; García-Sastre A; Shoichet BK; Craik CS
Protein Sci; 2023 Aug; 32(8):e4712. PubMed ID: 37354015
[TBL] [Abstract][Full Text] [Related]
14. COVID-19: inflammatory responses, structure-based drug design and potential therapeutics.
Tripathi N; Tripathi N; Goshisht MK
Mol Divers; 2022 Feb; 26(1):629-645. PubMed ID: 33400086
[TBL] [Abstract][Full Text] [Related]
15. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.
Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A
Molecules; 2020 May; 25(11):. PubMed ID: 32485894
[TBL] [Abstract][Full Text] [Related]
16. In Silico Discovery of Small-Molecule Inhibitors Targeting SARS-CoV-2 Main Protease.
Gao M; Kang D; Liu N; Liu Y
Molecules; 2023 Jul; 28(14):. PubMed ID: 37513194
[TBL] [Abstract][Full Text] [Related]
17. An Updated Review on SARS-CoV-2 Main Proteinase (M
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M
Ghosh A; Chakraborty M; Chandra A; Alam MP
J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023
[TBL] [Abstract][Full Text] [Related]
19. Structural biology of SARS-CoV-2 M
Duan Y; Wang H; Yuan Z; Yang H
Curr Opin Struct Biol; 2023 Oct; 82():102667. PubMed ID: 37544112
[TBL] [Abstract][Full Text] [Related]
20. High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors.
Zang Y; Su M; Wang Q; Cheng X; Zhang W; Zhao Y; Chen T; Jiang Y; Shen Q; Du J; Tan Q; Wang P; Gao L; Jin Z; Zhang M; Li C; Zhu Y; Feng B; Tang B; Xie H; Wang MW; Zheng M; Pan X; Yang H; Xu Y; Wu B; Zhang L; Rao Z; Yang X; Jiang H; Xiao G; Zhao Q; Li J
Protein Cell; 2023 Jan; 14(1):17-27. PubMed ID: 36726755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
